abs137.txt	background		angelman	syndrome	(as)	is	a	severe	neurodevelopmental	disorderlacking	effective	therapies		as	is	caused	by	mutations	in	ubiquitin	proteinligase	e3a	(ube3a)		which	is	genomically	imprinted	such	that	only	the	maternallyinherited	copy	is	expressed	in	neurons		we	previously	demonstrated	thattopoisomerase	i	(top1)	inhibitors	could	successfully	reactivate	the	dormantpaternal	allele	of	ube3a	in	neurons	of	a	mouse	model	of	as		we	also	previouslyshowed	that	one	such	top1	inhibitor		topotecan		could	unsilence	paternal	ube3a	ininduced	pluripotent	stem	cell-derived	neurons	from	individuals	with	as		althoughtopotecan	has	been	well-studied	and	is	fda-approved	for	cancer	therapy		itslimited	cns	bioavailability	will	likely	restrict	the	therapeutic	use	of	topotecanin	as		the	goal	of	this	study	was	to	identify	additional	top1	inhibitors	withsimilar	efficacy	as	topotecan		with	the	expectation	that	these	could	be	tested	inthe	future	for	safety	and	cns	bioavailability	to	assess	their	potential	as	astherapeutics	methods		we	tested	13	indenoisoquinoline-derived	top1	inhibitors	to	identifycompounds	that	unsilence	the	paternal	allele	of	ube3a	in	mouse	neurons		primarycortical	neurons	were	isolated	from	embryonic	day	14	5	(e14	5)	mice	with	aube3a-yfp	fluorescent	tag	on	the	paternal	allele	(ube3am+/pyfp	mice)	or	mice	thatlack	the	maternal	ube3a	allele	and	hence	model	as	(ube3am-/p+	mice)		neurons	werecultured	for	7	days		treated	with	drug	for	72	h		and	examined	for	paternal	ube3aprotein	expression	by	western	blot	or	fluorescence	immunostaining		dose	responsesof	the	compounds	were	determined	across	a	log	range	of	drug	treatments		andcytotoxicity	was	tested	using	a	luciferase-based	assay	results		all	13	indenoisoquinoline-derived	top1	inhibitors	unsilenced	paternalube3a		several	compounds	exhibited	favorable	paternal	ube3a	unsilencingproperties		similar	to	topotecan		and	of	these		indotecan	(lmp400)	was	the	mosteffective	based	on	estimated	emax	(maximum	response	of	unsilencing	paternalube3a)	and	ec50	(half	maximal	effective	concentration)	conclusions		we	provide	pharmacological	profiles	of	indenoisoquinoline-derivedtop1	inhibitors	as	paternal	ube3a	unsilencers		all	13	tested	compounds	wereeffective	at	unsilencing	paternal	ube3a		although	with	variable	efficacy	andpotency		indotecan	(lmp400)	demonstrated	a	better	pharmacological	profile	ofube3a	unsilencing	compared	to	our	previous	lead	compound		topotecan		takentogether		indotecan	and	its	structural	analogues	are	potential	as	therapeuticswhose	translational	potential	in	as	treatment	should	be	further	assessed	
